meso-scale-particle-image-velocimetry-studies-neurovascular-flows

Meso-Scale Particle Image Velocimetry Studies of Neurovascular Flows <em>In Vitro</em>

Particle image velocimetry (PIV) is used in a wide variety of fields, due to the opportunity it provides for precisely visualizing and quantifying flows ...

University of California, Los Angeles

To report our experience in treatment of arteriovenous malformations (AVMs) using a new liquid embolic agent, Onyx (Micro Therapeutics, Inc., Irvine, CA).

Embolization of arteriovenous malformations with Onyx: clinicopathological experience in 23 patients.

Stroke is the third most common cause of death in the United States following heart disease and cancer. Following the success of thrombolysis for myocardial infarction in the early 1990s, major trials for evaluation of this new therapeutic approach for ischemic stroke were initiated. The majority of ischemic strokes are due to occlusion of a cerebral vessel by a blood clot. Occlusion of a cerebral blood vessel leads to a core of infracted tissue surrounded by a relatively hypoperfused but viable brain tissue (the ischemic penumbra), which can be potentially salvaged by rapid recanalization of the target vessel. The underlying rationale for introduction of thrombolytic drugs is the lysis of an obliterating thrombus and reestablishment of blood flow. In this article we review the major intravenous thrombolysis trials leading to approval of intravenous recombinant tissue plasminogen activator, the only FDA approved treatment available today for acute ischemic stroke.

Hyperacute therapy of ischemic stroke: intravenous thrombolysis.

Ischemic stroke is a major cause of morbidity and mortality. Despite the fact that it is the third most common cause of death in the United States, there is only one FDA approved treatment for patients. This is Intravenous recombinant tissue plasminogen activator given within 3 hours of symptom onset. Furthermore, despite the approval of this drug, it has been underutilized in the community. The limited time window of 3 hours disqualifies many patients from receiving the drug. In addition, fears of intracranial hemorrhage have resulted in underutilization of the drug in the community setting. Efforts to increase the time window to treatment include utilization of the intraarterial route for delivery of thrombolytic drug and interventional mechanical strategies to revascularize intracranial vessels. In this report we review the major intraarterial thrombolysis trials and review the mechanical strategies being developed to treat patients with acute ischemic stroke.

Hyperacute therapy of acute ischemic stroke: intraarterial thrombolysis and mechanical revascularization strategies.

Stereotactic radiosurgery is an established, effective treatment for brain arteriovenous malformations. The mechanisms of vessel occlusion in arteriovenous malformations has not been extensively evaluated. To better understand these mechanisms, we report histopathological changes in the swine rete mirabile after stereotactic radiosurgery.

Stereotactic radiosurgery of the rete mirabile in swine: a longitudinal study of histopathological changes.

To introduce the utilization of a swine arteriovenous malformation (AVM) model for stereotactic radiosurgery research and to describe the morphological changes in the vessels after radiation.

An arteriovenous malformation model for stereotactic radiosurgery research.

Stroke is the third most common cause of death in the USA, following heart disease and cancer. Intravenous recombinant tissue plasminogen activator is the only US FDA-approved pharmacological treatment available today for acute ischemic stroke. Despite the approval of this drug, it has been underutilized in the community. The limited time window of 3 h disqualifies many patients from receiving the drug. In addition, fears of intracranial hemorrhage have resulted in underutilization of the drug in the community setting. Efforts to increase the time window of treatment include utilization of the intra-arterial route for delivery of a thrombolytic drug and interventional mechanical strategies. In this article, we review the major intravenous and intra-arterial thrombolysis trials and review the mechanical strategies being developed to treat patients with acute ischemic stroke.

Treatment of acute ischemic stroke: intravenous and endovascular therapies.

The extended time window and theoretic reduction in hemorrhage make mechanical strategies an attractive approach in the treatment of patients with ischemic stroke. My purpose was to evaluate the recanalization efficacy and safety of the Solitaire FR Revascularization Device in a swine vessel occlusion model.

Article	Year
Embolization of arteriovenous malformations with Onyx: clinicopathological experience in 23 patients. Neurosurgery\| PubMed ID: 11334300	2001
Hyperacute therapy of ischemic stroke: intravenous thrombolysis. Techniques in vascular and interventional radiology\| PubMed ID: 16194755	2005
Hyperacute therapy of acute ischemic stroke: intraarterial thrombolysis and mechanical revascularization strategies. Techniques in vascular and interventional radiology\| PubMed ID: 16194756	2005
Stereotactic radiosurgery of the rete mirabile in swine: a longitudinal study of histopathological changes. Neurosurgery\| PubMed ID: 16528197	2006
An arteriovenous malformation model for stereotactic radiosurgery research. Neurosurgery\| PubMed ID: 17621031	2007
Treatment of acute ischemic stroke: intravenous and endovascular therapies. Expert review of cardiovascular therapy\| PubMed ID: 19379062	2009
Solitaire flow-restoration device for treatment of acute ischemic stroke: safety and recanalization efficacy study in a swine vessel occlusion model. AJNR. American journal of neuroradiology\| PubMed ID: 20634306	2010

Reza Jahan

Biography

JoVE Journal Publications

Other Publications